secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRYO CELL INTERNATIONAL INC (CCEL)
CIK:        0000862692
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0000950170-23-007079
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryo-Cell amends Duke license, adds milestone for autism MSC therapy; funds IMPACT study
--------------------------------------------------------------------------------

- Second Amendment removes final license fee payment to Duke; license fee now paid in full.
- New milestone payment triggered upon FDA approval of first cord tissue MSC product for autism spectrum disorder.
- New milestone requires Cryo-Cell to open manufacturing facility for licensed product before Phase III trial initiation.
- Cryo-Cell entered Research Agreement to fund Duke IMPACT Study; 14 monthly payments starting April 2023.
- IMPACT Study targeted accrual reached: 137 patients; draft publication due no later than September 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/862692/000095017023007079/0000950170-23-007079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/862692/000095017023007079/ccel-20230303.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer